Peripheral endocannabinoid system dysregulation in first-episode psychosis.
Subject: Schizophrenia - PUBLISHED VIA Neuropsychopharmacology
Author(s):
Bioque M, García-Bueno B, Macdowell KS, Meseguer A, Saiz PA, Parellada M, Gonzalez-Pinto A, Rodriguez-Jimenez R, Lobo A, Leza JC, Bernardo M; FLAMM-PEPs study—Centro de Investigacio´n Biome´dica en Red de Salud Mental
View Source >>
Related Studies:
Medical use of cannabis. Cannabidiol: a new light for schizophrenia?
Published via Drug Testing and Analysis
Cannabidiol as a potential treatment for psychosis.
Published via European Neuropsychopharmacology
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.
Published via Translational Psychiatry
Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
Published via Brazilian Journal of Medical and Biological Research
A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.
Published via Current Pharmaceutical Design